Imagine Pharma is a biotechnology company focused on the development of its IMG-1 polypeptide. Research and development efforts have led to the development of three distinctive platforms for Oral Delivery, Therapeutics, and Regenerative Medicine, each with first-in-class programs that address multiple disease states in large, underserved markets. Imagine Pharma is an approved Islet Isolation Center for the National Institute of Diabetes and Digestive and Kidney Diseases Integrated Islet Distribution Program. Imagine Pharma was founded in 2016.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/31/23 | $32,500,000 | Series A |
IP Investors LLC | undisclosed |
